Protein from Colonic Tissue Associated with Parkinson's
By LabMedica International staff writers Posted on 29 May 2012 |
Two studies suggest that colonic tissue obtained during either colonoscopy or flexible sigmoidoscopy may be used to predict who will develop Parkinson’s disease.
A protein called alpha-synuclein is deposited in cells of the brain of patients with Parkinson’s disease and is considered a pathologic hallmark of the disorder. These protein aggregates form Lewy bodies, a characteristic structure seen in Parkinson's disease brains at autopsy.
Physicians at Rush University (Chicago, IL, USA) demonstrated that the alpha-synuclein protein could also be seen in the nerve cells in the wall of the intestines in subjects with early Parkinson’s disease, but not in healthy subjects. Ten subjects with early Parkinson’s disease had flexible sigmoidoscopy. The scientists demonstrated alpha-synuclein aggregation in biological tissue obtained before onset of motor symptoms of Parkinson’s disease.
The studies were conducted by Dr. Kathleen M. Shannon, neurologist in the Movement Disorders and Parkinson’s Center at Rush, and a multidisciplinary team of scientists from the university. They also analyzed samples of tissue obtained during colonoscopy examinations that took place 2-5 years before the first symptom of Parkinson’s disease appeared in three subjects, and all three showed the characteristic protein in the wall of the lower intestine.
The studies were published the May 15, 2012, issue of the journal Movement Disorders.
Currently, Parkinson’s disease afflicts almost 5 million people worldwide. A neurodegenerative disorder of aging, it leads to progressive deterioration of motor function due to loss of neurons in the brain that produce dopamine, a neurotransmitter essential to executing movement.
“Recent clinical and pathological evidence supports the notion that Parkinson’s disease may begin in the intestinal wall then spread through the nerves to the brain. Clinical signs of intestinal disease, such as constipation, [may precede] Parkinson’s disease diagnosis by more than a decade. These studies suggest it may one day be possible to use colonic tissue biopsy to predict who will develop motor Parkinson’s disease,” said Dr. Shannon.
“Such tissue could be obtained at the time of screening colonoscopy, a procedure routinely applied for colon cancer surveillance beginning at age 50 and repeated every three to 10 years in adults of middle age,” Dr. Shannon added.
Alternatively, the Rush investigators showed that colonic tissue is easily obtained using flexible sigmoidoscopy, a technique that, unlike colonoscopy, requires no colon cleansing preparation or sedation, and can be performed in 10 minutes.
“In view of a multibillion-dollar translational research effort that aims to identify agents that slow or stop the progression of Parkinson’s disease, the need for accurate and timely diagnostic biomarkers, including the potential for premotor diagnosis, is particularly acute,” the authors stated. “We believe that alpha-synuclein in the colonic submucosa may be a premotor biomarker that easily can be studied in cohorts at increased risk of developing Parkinson’s disease.
The Rush scientists stressed that their finding must be replicated in other populations, including other neurodegenerative Parkinson’s-like disorders, and to determine the safest and highest-yield biomarker site.
Related Links:
Rush University
A protein called alpha-synuclein is deposited in cells of the brain of patients with Parkinson’s disease and is considered a pathologic hallmark of the disorder. These protein aggregates form Lewy bodies, a characteristic structure seen in Parkinson's disease brains at autopsy.
Physicians at Rush University (Chicago, IL, USA) demonstrated that the alpha-synuclein protein could also be seen in the nerve cells in the wall of the intestines in subjects with early Parkinson’s disease, but not in healthy subjects. Ten subjects with early Parkinson’s disease had flexible sigmoidoscopy. The scientists demonstrated alpha-synuclein aggregation in biological tissue obtained before onset of motor symptoms of Parkinson’s disease.
The studies were conducted by Dr. Kathleen M. Shannon, neurologist in the Movement Disorders and Parkinson’s Center at Rush, and a multidisciplinary team of scientists from the university. They also analyzed samples of tissue obtained during colonoscopy examinations that took place 2-5 years before the first symptom of Parkinson’s disease appeared in three subjects, and all three showed the characteristic protein in the wall of the lower intestine.
The studies were published the May 15, 2012, issue of the journal Movement Disorders.
Currently, Parkinson’s disease afflicts almost 5 million people worldwide. A neurodegenerative disorder of aging, it leads to progressive deterioration of motor function due to loss of neurons in the brain that produce dopamine, a neurotransmitter essential to executing movement.
“Recent clinical and pathological evidence supports the notion that Parkinson’s disease may begin in the intestinal wall then spread through the nerves to the brain. Clinical signs of intestinal disease, such as constipation, [may precede] Parkinson’s disease diagnosis by more than a decade. These studies suggest it may one day be possible to use colonic tissue biopsy to predict who will develop motor Parkinson’s disease,” said Dr. Shannon.
“Such tissue could be obtained at the time of screening colonoscopy, a procedure routinely applied for colon cancer surveillance beginning at age 50 and repeated every three to 10 years in adults of middle age,” Dr. Shannon added.
Alternatively, the Rush investigators showed that colonic tissue is easily obtained using flexible sigmoidoscopy, a technique that, unlike colonoscopy, requires no colon cleansing preparation or sedation, and can be performed in 10 minutes.
“In view of a multibillion-dollar translational research effort that aims to identify agents that slow or stop the progression of Parkinson’s disease, the need for accurate and timely diagnostic biomarkers, including the potential for premotor diagnosis, is particularly acute,” the authors stated. “We believe that alpha-synuclein in the colonic submucosa may be a premotor biomarker that easily can be studied in cohorts at increased risk of developing Parkinson’s disease.
The Rush scientists stressed that their finding must be replicated in other populations, including other neurodegenerative Parkinson’s-like disorders, and to determine the safest and highest-yield biomarker site.
Related Links:
Rush University
Latest Pathology News
- AI Tool Accurately Determines Breast Cancer Prognosis
- Powerful New Tool Improves Tissue Cancer Analysis
- AI-Based Tool Measures Cancer Aggressiveness
- Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels
- New AI-Based Method Effectively Identifies Disease Phenotypes Using Light-Based Imaging
- AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care
- AI Tool Enhances Interpretation of Tissue Samples by Pathologists
- AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
- Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
- New Lab Model to Help Find Treatments for Aggressive Blood Cancer
- AI-Supported Microscopy Improves Detection of Intestinal Parasite Infections
- AI Performs Virtual Tissue Staining at Super-Resolution
- AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis
- Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
- Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
- Saliva-Based Testing to Enable Early Detection of Cancer, Heart Disease or Parkinson’s
Channels
Clinical Chemistry
view channel
Skin Swabs Could Detect Parkinson’s Years Before Symptoms Appear
Parkinson’s disease is notoriously difficult to diagnose in its early stages, as motor symptoms do not appear until later in the progression of the disease. The ability to detect the disease up to seven... Read more
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreMolecular Diagnostics
view channel
Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis
Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more
New Gene Tool to Enable Earlier Detection and Treatment of Cardiometabolic Diseases
Cardiometabolic diseases, which affect the heart, blood vessels, and the body's ability to process food and generate energy, are difficult to diagnose early due to the complex genetic changes that contribute... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy
To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more
Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer
Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more
Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes
Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read moreMicrobiology
view channel
Early Detection of Gut Microbiota Metabolite Linked to Atherosclerosis Could Revolutionize Diagnosis
Cardiovascular disease is the leading cause of death worldwide, and atherosclerosis plays a critical role in its development. This chronic condition, characterized by the hardening and narrowing of arteries... Read more
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read moreTechnology
view channel
Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells
A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Safer, Portable and Low-Cost Imaging Solution to Revolutionize Biomedical Diagnostics
In diagnosing diseases and monitoring treatment, accurate and quick detection of temperature within biological tissues can be crucial, especially in early disease detection. Conventional methods such as... Read more
Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation
Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read moreIndustry
view channel
QuidelOrtho and BÜHLMANN Collaborate on Gastrointestinal Biomarker Tests
QuidelOrtho Corporation (San Diego, CA, USA) and BÜHLMANN Laboratories AG (Schönenbuch, Switzerland) have announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's... Read more